Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial

Journal of Clinical Oncology

Volumn 22, Issue 7, 2004, Pages 1301-1307

  Auerbach, Michael ^a   Ballard, Harold ^a   Trout, J Richard ^a   McIlwain, Marilyn ^a   Ackerman, Alan ^a   Bahrain, Huzefa ^a   Balan, Stefan ^a   Barker, Lance ^a   Rana, Jeevindra ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ANTINEOPLASTIC AGENT; IRON DEXTRAN;

ANEMIA; ARTICLE; CANCER PATIENT; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; ENERGY; FERRITIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; AGED; CONGENITAL MALFORMATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, ORAL; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; IRON-DEXTRAN COMPLEX; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 2142825053     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.119     Document Type: Article

References (27)

1. Miller CB, Jones RJ, Piantadosi S, et al: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1692, 1990
2. Means RT Jr, Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80:1639-1647, 1992
3. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 91:1616-1634, 1999
4. Birgegard G, Ludwig H, Nortier JWR, et al: Despite high prevalence of anemia and impact on performance status (PS), anemia treatment (Tx) rate is low in multiple myeloma/lymphoma (MM/L) patients (pts) according to European Cancer Anaemia Survey (ECAS). Blood 100:18b, 2002 (abstr 3521)
5. Ludwig H, Birgegard G, Barrett-Lee P, et al: Prevalence and management of anemia in patients (pts) with hematologic malignancies (HMs) and solid tumors (STs): results from the European Cancer Anaemia Survey (ECAS). Blood 100:234a-235a, 2002 (abstr 884)
6. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol 15:1218-1234, 1997
7. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study-Procrit Study Group. J Clin Oncol 16:3412-3425, 1998
8. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
9. Littlewood TJ, Bagetta E, Nortier JWR, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
10. Quirt I, Robeson C, Lau CY, et al: And the Canadian Eprex Oncology Study Group: Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19:4126-4134, 2001
11. Fallowfield L, Gagnon D, Zagari M, et al: For the Epoetin Alfa Study Group: Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 87:1341-1353, 2002
12. Bokemeyer C, Oechsle K, Hartmann JT, et al: Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 87:1066-1071, 2002
13. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
14. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
15. Macdougall IC, Tucker B, Thompson J, et al: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1996
16. Sepandj F, Jindal K, West M, et al: Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11:319-322, 1996
17. Cazzola M, Mercuriali F, Brugnara C: Use of recombinant human erythropoietin outside the setting of uremia. Blood 89:4248-4267, 1997
18. Fishbane S, Ungureanu V-D, Maesaka JK, et al: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529-534, 1996
19. INFeD (iron dextran injection, USP) [package insert]: Watson Pharma, Inc., Morristown, NJ; February 2001
20. Auerbach M, Chaudry M, Goldman H, et al: Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with total dose infusion of iron dextran: A double blind randomized trial. J Lab Clin Med 131:257-260, 1998
21. Auerbach M, Witt D, Toler W, et al: Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 111:566-570, 1988
22. Henry DH: Supplemental iron: A key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 3:275-278, 1998
23. Markowitz GS, Kahn GA, Feingold RE, et al: An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 48:34-40, 1997
24. Kooistra MP, Niemantsverdriet EC, van Es A, et al: Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 13:82-88, 1998
25. Michael B, Coyne DW, Fishbane S, et al: For the Ferrlecit Publication Committee: Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions when compared to placebo and iron dextran. Kidney Int 61:1830-1839, 2002
26. Coyne DW, Adkinson NF Jr, Nissenson AR, et al: Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 63:217-224, 2003
27. Henke M, Laszig R, Rube C, et al: Erythropoietin to treat and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260, 2003